MCL1 and non-small cell lung carcinoma: In summary, our data show that genomic gains of MCL-1 during lung cancer evolution represent a frequent and functionally important survival mechanism for pulmonary adenocarcinoma that represents a rational drug target for the treatment of NSCLC.